Meet Dr. Benjamin Greenberg
Autoimmune Disorders Expert in Dallas
- Holder of the:
- Cain Denius Scholar in Mobility Disorders
Neurologist Dr. Benjamin Greenberg is an internationally recognized expert in treating adults and children with autoimmune disorders of the central nervous system. He specializes in treating patients with transverse myelitis (TM), neuromyelitis optica (NMO, or Devic’s disease), and multiple sclerosis (MS), as well as children with TM, MS, and other conditions such as autoimmune encephalitis and acute demyelinating encephalomyelitis (ADEM).
Because the diseases are rare, patients can have a hard time finding a medical “home” – a place where the clinicians specialize in treating and better understanding these complex, sometimes debilitating conditions. Dr. Greenberg and the team at UT Southwestern Medical Center offer that home, treating patients from around the world with these disorders.
“It’s been very rewarding to help create a team that has virtually no match in terms of the variety and depth of highly specialized skill sets we offer,” Dr. Greenberg says.
As an example, one common misconception people have about demyelinating diseases is that after an acute event, the recovery time is limited. Some nonspecialists tell patients with transverse myelitis that the function they will recover will be within six to 12 months of the event will be the limit of their recovery.
“Our work and experience has shown us that’s just not the case,” Dr. Greenberg says. “We see adults and children recover function years out from acute events. We often have to remind people that there’s not a time limit on their window for recovery.”
A three-time Texas Monthly Rising Star, Dr. Greenberg believes that UT Southwestern’s multidisciplinary, evidence-based approach is the key to delivering the best care available – both acute and long-term.
“We have a team of experts who are passionate about helping patients with these conditions, and taking an active presence on the national and international stage in understanding and defining treatment options.”